z-logo
open-access-imgOpen Access
Detection of CTX-M-type ESBLs from Escherichia coli Clinical Isolates from a Tertiary Hospital, Malaysia
Author(s) -
Mkk Et al.
Publication year - 2019
Publication title -
mağallaẗ baġdād li-l-ʿulūm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.167
H-Index - 6
eISSN - 2411-7986
pISSN - 2078-8665
DOI - 10.21123/bsj.2019.16.3(suppl.).0682
Subject(s) - meropenem , imipenem , cefotaxime , microbiology and biotechnology , ampicillin , antibiotics , escherichia coli , biology , carbapenem , cefuroxime , cephalosporin , cefepime , piperacillin , antibiotic resistance , bacteria , pseudomonas aeruginosa , gene , biochemistry , genetics
The present study aims to detect CTX-M-type ESBL from Escherichia coli clinical isolates and to analyze their antibotic susceptibility patterns. One hundred of E. coli isolates were collected from different clinical samples from a tertiary hospital. ESBL positivity was determined by the disk diffusion method. PCR used for amplification of CTX-M-type ESBL produced by E. coli. Out of 100 E. coli isolates, twenty-four isolates (24%) were ESBL-producers. E. coli isolated from pus was the most frequent clinical specimen that produced ESBL (41.66%) followed by urine (34.21%), respiratory (22.23%), and blood (19.05%).  After PCR amplification of these 24 isolates, 10 (41.66%) isolates were found to possess CTX-M genes. The CTX-M type ESBL producing E. coli against antibiotics belonging to different families showed the highest resistance rates to Ampicillin (100%), Cefotaxime (97%), Cefuroxime (95%), and Ciprofoxacin (86%). Carbapenem groups of antibiotics, Meropenem (89%) and Imipenem (85%) have the highest susceptibility rate among all antibiotics used in this study. The outcome of the antimicrobial susceptibility testing of significant CTX-M- type ESBL producing E. coli could be useful to avoid failure or prolong treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here